P
Palivizumab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Subsidy Information and Financing Scheme
No
Active ingredient: Palivizumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended palivizumab for inclusion on the MOH List of Subsidised Drugs for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease, because it does not represent a cost-effective use of healthcare resources at the price proposed by the company.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Synagis Injection, Solution 100 mg/mL |
|